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1. LITERATURE OVERVIEW 
 
1.1. INCIDENCE 
Glioblastoma multiforme (GBM) is the most feared type of primary central 
nervous system (CNS) cancer, not only for poor prognosis, but also because of 
the direct influence on the quality of life and cognitive function. GBM accounts 
for approximately 20–45% of all malignant primary CNS tumors and 82% of 
high grade (WHO grades III and IV) gliomas [1–3].  
Overall, about 27,700 new CNS primary cancers are diagnosed every year in 
Europe, with an annual incidence rate of 4.8 per 100000 person-years for astro-
cytic tumors (including GBM) [4]. Nevertheless, for malignant tumors, the 
incidence rates are highest for GBM, being approximately 2–3 cases per 100000 
person-years in most European and North-American countries [5,3]. The inci-
dence rates of GBM in Estonia are 1.8 cases per 100000 person-years in females 
and 2.2 cases per 100000 person-years in males [6].  
The incidence of GBM increases with age, being more common in older 
adults and uncommon in children. The average age at diagnosis of GBM is 64 
years of age and, for reasons yet unclear, it has demonstrated a clear male 
predilection, being about 1.57 times more common in males than females [3]. 
 
 
1.2. SURVIVAL 
Despite aggressive and combined therapy, median survival of GBM patients is 
still unsatisfactory, extending only up to 15 months [7]. However, few patients 
with GBM (3–5%) survive for more than 3 years and are referred to as long-
term survivors [8]. The relative survival estimates for glioblastoma are quite 
low, since less than 5% of patients survive five years post diagnosis [3,9]. GBM 
survival estimates are somewhat higher for the small number of patients who 
are diagnosed under the age of 20 [3]. Nevertheless, survival times of GBM 
patients have remained largely unchanged for more than 50 years, pointing 
toward the urgent need for more effective treatment choices [10].  
 
 
1.3. CLASSIFICATION AND DESCRIPTION 
The World Health Organization (WHO) classification system groups gliomas 
into 4 histological grades defined by increasing degrees of undifferentiation, 
anaplasia, and aggressiveness [11,12]. Grade I tumors are biologically benign 
and total removal leads to recovery. Grade II tumors are low-grade malignan-
cies that may follow long clinical courses, but early diffuse infiltration of the 
surrounding brain renders them often not totally resectable. Grade III tumors 
exhibit aggressive behaviour characterized by increased anaplasia and mitosis 
over grade II tumors and due to this biological pattern, these tumors progress 
rather quickly. Grade IV tumors, also known as GBM, exhibit more advanced 
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features of malignancy, including vascular proliferation and necrosis and are 
often refractory to radiotherapy or chemotherapy [13,14]. Figure 1 illustrates 
characteristic histological features of GBM (abundant angiogenesis, glomeru-
loid vascular proliferations and necrosis). 
 
 
 
 
Figure 1. Histological characteristics of GBM 
Histological hallmarks of GBM are: abundant angiogenesis (A, x40), microvascular 
proliferations (MP) (B, x40), and necrosis (C, x10).  
 
 
GBM is the most malignant of all astrocytic tumors. GBM is defined by the 
hall-mark features, such as uncontrolled cellular proliferation, diffuse infiltra-
tion, propensity for necrosis, robust angiogenesis, intense resistance to apopto-
sis, and genomic instability [15]. GBM presents with significant intratumoral 
heterogeneity on the cytopathological, transcriptional, and genomic levels. This 
complexity, combined with a putative cancer stem cell (CSC) subpopulation 
and an incomplete (epi)genetic lesions driving GBM pathogenesis, make this 
cancer one of the most difficult to understand and to treat [15].  
On the basis of clinical presentation, GBMs have been further subdivided into 
the primary or secondary GBM subtypes [13]. Primary GBMs account for the great 
majority of GBM cases in older patients, while secondary GBMs are quite rare and 
tend to occur in patients below the age of 45 year. Primary GBM presents in an 
acute de novo manner with no evidence of a prior symptoms or antecedent lower 
grade pathology. In contrast, secondary GBM derives consistently from the pro-
gressive transformation of lower grade astrocytomas, with approximately 70% of 
grade II gliomas transforming into grade III/IV disease within 5–10 year of 
diagnosis [14]. Moreover, only 5% of all cases estimated as secondary glio-
blastomas have histopathological evidence of a precursor low-grade or anaplastic 
astrocytoma [16]. Remarkably, despite their distinct clinical histories, primary and 
secondary GBMs are morphologically and clinically indistinguishable as reflected 
by an equally poor prognosis when adjusted for patient age [14]. 
In majority of patients, GBM occurs as a local disease affecting different 
parts of the brain. However, in rare cases, distant metastases in other organs 
may develop. For example, the presence of metastatic lesions of GBM have 
been described in bones [17–20], lungs [21,18,22–24], heart [24], spleen [25], 
liver [26], cutaneous and subcutaneous tissue [27,28], parotid gland [29–31] and 
lymph nodes [32–34]. It is believed that metastatic glioblastoma cells, like other 
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types of cancer cells, use common dissemination pathways, such as blood and 
lymphatic vessels [35]. Also, next to previously described ways, extraneural 
spread of GBM has been reported [36]. 
 
 
1.4. HEREDITARY SYNDROMES AND  
GENETIC PROFILE 
Most GBMs appear to be sporadic, without any genetic predisposition. Never-
theless, a number of hereditary syndromes are associated with an increased risk 
of glioma, including Cowden, Turcot, Li-Fraumeni and von Hippel-Lindau 
syndromes, as well as neurofibromatosis type 1 and type 2, tuberous sclerosis 
and familial schwannomatosis [9]. This suggests a putative genetic relationship 
but in a small minority, approximately 5% of GBM patients [37]. 
Loss of heterozygosity (LOH) on chromosome arm 10q is the most frequent 
gene alteration for both primary and secondary GBMs [16]. LOH occurs in up 
to 80% of GBM cases and it is reported to be more extensive in primary than in 
secondary GBMs [38]. Mutations in p53, a tumor suppressor gene, are more 
commonly seen in secondary GBM [39]. These mutations are present in more 
than two-thirds of secondary GBMs but rarely seen in primary GBM [16]. 
Epidermal growth factor receptor (EGFR) amplification has been identified as a 
genetic hallmark of primary glioblastomas that occurs in 40–60% of cases 
[40,41]. Amplification or overexpression of MDM2 gene constitutes an alterna-
tive mechanism to escape from p53-regulated control of cell growth. Over-
expression of MDM2 is the second most common gene mutation in GBM [16]. 
Platelet-derived growth factor alpha (PDGFA) gene acts as a major mitogen for 
glial cells. Platelet-derived growth factor receptor alpha (PDGFRA) over-
expression and isocitrate dehydrogenase 1 (IDH1) mutations are some of the 
major genetic alterations found in low grade gliomas, as well as secondary 
GBMs. When the low grade tumors progress toward the high grade secondary 
GBMs, additional changes such as CDK-dependent kinase inhibitor (CDKN2A/ 
CDKN2B) deletion are acquired [42]. PTEN (phosphatase and tensin homolog 
also known as MMAC and TEP1) encodes a tyrosine phosphatase located at 
band 10q23.3. Loss of PTEN function is the most common alteration in primary 
but not in secondary GBMs [43].  
 
 
1.5. RISK FACTORS 
The specific cause of GBM is unknown and identifying various risk factors has 
proven difficult. However, the cause-effect relationship between ionizing radia-
tion and the development of GBM was established with studies that de-
monstrated that children treated with radiotherapy for malignancies like leuke-
mia have a markedly increased risk for developing GBM [44]. Additionally, the 
use of cell phones that are known to release a small amount of non-ionizing 
electromagnetic radiation, has been suggested as possible risk factor for glio-
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mas, especially in the cases of long-term use [45]. Pesticide exposure (possibly 
also during pregnancy), is associated with an increased childhood brain tumors 
risk but no positive association of farm pesticide exposure and glioma risks in 
adults has been identified [46,47]. Head trauma has been suggested as a possible 
risk factor for developing GBM. Although epidemiological studies do not sup-
port a definitive connection between head injury and intracranial glioma, there 
are few case reports of post-traumatic gliomas published [48–53]. Family 
history of any cancer probably is not an important risk factor for adult glioma, 
however, a family history of brain tumors may play a role [54]. Previous studies 
have also found that gliomas are inversely associated with the presence of 
atopic diseases such as asthma, eczema, and hay fever [55]. It has also been 
suggested that viral infections (e.g. human herpesvirus 6, cytomegalovirus, 
simian virus 40) may be associated with the development of GBM by tumori-
genesis through integration of viral genetic material into normal DNA [56–58].  
Preventive measures, such as lifestyle and dietary changes, are ineffective in 
averting gliomas [59]. Moreover, early diagnosis and treatment unfortunately do 
not improve outcomes, precluding the utility of screening for this disease [60]. 
 
 
1.6. CLINICAL PRESENTATION 
The clinical history of patients with GBM is usually short, being less than 3 
months in more than 50% of patients, unless the neoplasm has developed from a 
lower-grade astrocytoma [61,62]. Figure 2 illustrates a clinical course of GBM 
patient treated at Tartu University Hospital. In this patient, symptoms (mainly 
headache) lasted for 3 months before final diagnosis of GBM was established 
after surgery. 
 
 
 
Figure 2. Clinical course of GBM patient treated at Tartu University Hospital 
Computer tomography images were obtained at the time of first onset of headache (left, 
January 2012) and 3 months later (right, April 2012). On the first CT image, tumor was 
not visible but 3 months later contrast-enhancing tumor and very extensive peritumoral 
oedema were present.  
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The character of the symptoms depends highly on the location of the tumor. 
Common symptoms of GBM include headache, seizures, nausea, vomiting and 
hemiparesis, however, due to temporal and frontal lobe involvement (most fre-
quent sites of GBM) symptoms such as progressive memory and neurological 
deficits, as well as personality changes may develop [63,64]. 
Headaches are relatively frequent, present in about 50% of patients at diag-
nosis, but usually with a nonspecific pain pattern [65]. Progressive severity, 
unilateral localization, and new-onset headache in a patient older than 50 years 
are some of the features that may distinguish a tumor-associated headache from 
a benign headache [9]. Seizures manifest in about 20% to 40% of patients, and 
usually a focal onset is reported [66]. As described earlier, cognitive difficulties 
and personality changes may develop and are often mistaken for psychiatric 
disorders or dementia, particularly in elderly individuals [9]. Focal signs such as 
hemiparesis, sensory loss, or visual field disturbances are common and reflect 
tumor location. Also, gait imbalance and incontinence may be present, usually 
in larger tumors with significant mass effect. Papilledema is associated with 
significantly increased intracranial pressure and is now rarely seen because 
imaging is usually obtained at earlier disease stages. Occasionally, the develop-
ment of symptoms is rapid, mimicking a stroke. Speech disorder may be mis-
taken for confusion or delirium [9].  
 
 
1.7. PROGNOSTIC FACTORS 
Radiation Therapy Oncology Group (RTOG) has proposed a prognostic score 
of malignant gliomas based on patient and tumor features (age, Karnofsky 
performance Status (KPS), extent of surgery) [67]. The European Organisation 
for Research and Treatment of Cancer and NCIC Clinical Trials Group 
(EORTC/NCIC) confirmed the prognostic value of recursive partitioning ana-
lysis including only GBM patients [68]. Additionally, German Glioma Network 
findings underline the association of GBM long-term survival with prog-
nostically favourable clinical factors, in particular young age and good initial 
performance score, as well as O6-methylguanine-DNA methyltransferase 
(MGMT) gene promoter hypermethylation [8]. Also, a 20% reduction in the 
hazards of mortality in patients with a specific histological form (giant cell 
GBM) compared to GBM has been reported [69]. 
 
 
1.8. TREATMENT 
Unfortunately, none of GBM treatment choices is curative.  
Upon initial diagnosis of GBM, standard treatment consists of maximal 
surgical resection, radiotherapy, and concomitant and adjuvant chemotherapy 
with temozolomide (TMZ) [14,7,9]. For older patients, less aggressive therapy 
is sometimes suggested, using radiation or chemotherapy alone [70,71].  
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1.8.1. Surgery 
Surgery is the first therapeutic modality for GBM.  
After neuroimaging, patients with suspected malignant glioma should be 
considered for surgical resection, aiming at relieving mass effect, achieving 
cytoreduction, and providing adequate tissue for histologic and molecular tumor 
characterization [9]. In inoperable tumors, stereotactic biopsy may be performed 
for histologic diagnosis, but the limited amount of tissue acquired may preclude 
full molecular characterization.  
The goal of surgery is to achieve gross total resection of the contrast 
enhancing component of the tumor (seen in Magnetic Resonance Imaging, MRI), 
without compromising neurological function (maximal safe resection) [72]. In 
some circumstances, gross total resection may not be possible based on anatomic 
structures invaded by the tumor. Advances in surgical imaging techniques, such 
as intraoperative ultrasound and MRI, diffusion tensor imaging, awake cranio-
tomy, cortical mapping, stereotactic guidance, and fluorescent-guided resection, 
have facilitated delineation of tumor borders and can help optimize maximal safe 
surgical resection [73,74,72]. Therefore, whenever possible, patients should be 
referred for surgery in tertiary care facilities, which provide optimized surgical 
tools (advanced intraoperative monitoring, awake mapping, and functional and 
intraoperative MRI) and allow for adequate handling, processing, and storage of 
the tissue, including comprehensive molecular characterization and tissue pro-
filing that may guide subsequent treatments [9,75]. 
 
 
1.8.2. Radiotherapy 
Although maximal surgical resection remains important, more than 90% of pa-
tients with glioma show recurrence at the original tumor location or within 2 to 
3 cm from the border of the original lesion [76–78]. Therefore, surgical re-
section is combined with adjuvant therapy to prolong survival.  
Since 1978, patients with GBM have been treated by debulking surgery (to the 
extent that is safely feasible) and postoperative radiotherapy [79]. Radiation 
therapy (RT) uses controlled high-energy rays to kill cancer cells by damaging 
directly or indirectly the DNA inside cells making them unable to divide or 
reproduce and delay a recurrence of the tumor. Abnormal cancer cells are more 
sensitive to radiation because they divide more quickly than normal cells. Over 
time, the abnormal cells die and the tumor shrinks. Normal cells can also be 
damaged by RT, but they can repair themselves more effectively. The area where 
the radiation is delivered (called the radiation field) is carefully calculated to 
include the smallest possible amount of normal brain as possible, so called the 
“involved field” (the original area of the tumor plus a small margin around).  
The current standard of care for RT in GBM is focal, fractionated external 
beam radiation therapy (EBRT) to the surgical resection cavity and to a 2–3 cm 
margin of surrounding brain tissue. Usually, 60 Gy of RT is delivered in 
fractions of 2 Gy over 6 weeks [7]. Although radiotherapy is still the corner-
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stone adjuvant treatment in GBM, at the present, the combination of RT plus 
chemotherapy with temozolomide (TMZ) is the most efficacious adjuvant 
therapy after primary resection. Treatment following surgery usually consists of 
6 weeks of RT to the surgical cavity and concomitant TMZ, followed by 6 
adjuvant cycles of TMZ [7]. 
 
 
1.8.3. Chemotherapy 
Chemotherapy refers to the use of medicines to stop or slow the growth of 
cancer cells. Chemotherapy works by interfering with the ability of rapidly 
growing cells (like cancer cells) to divide. Because most of an adult's normal 
cells are not actively growing, they are not affected by chemotherapy, with the 
exception of bone marrow (where blood cells are produced), the hair, and the 
lining of the gastrointestinal tract. Effects of chemotherapy on these and other 
normal tissues cause side effects during treatment. 
Up to 2005, chemotherapy had no demonstrable clinical benefit in GBM, and 
RT alone remained the standard of care after surgical resection [72]. However, in 
2005, a clinical trial demonstrated that concurrent RT and TMZ followed by adju-
vant TMZ significantly prolonged the median survival more than that of radiation 
alone (14.6 months versus 12.1 months; p < 0.001). These findings established the 
therapeutic benefit of TMZ in combination with RT, establishing the so-called 
“Stupp regimen”, standard of care for GBM treatment [7]. 
TMZ is an oral alkylating chemotherapeutic agent that causes DNA damage 
and triggers a cascade of events leading to tumor cell apoptosis [72]. Previous 
studies have shown that patients with an unmethylated DNA repair enzyme O6-
methylguanine-DNA methyltransferase (MGMT) gene are much less responsive 
to TMZ, whereas MGMT methylation confers sensitivity to TMZ in patients 
with GBM [9,72]. 
Implantation of carmustine wafers into the resection cavity is another ap-
proved treatment of GBM [80]. Similar to TMZ, carmustine is a DNA alky-
lating agent. Carmustine is released into the surrounding brain tissue immedia-
tely after tumor resection and its effect last for several weeks [73]. In clinical 
trials, carmustine wafers used in combination with radiation and TMZ have 
been shown to modestly prolong survival in subsets of patients. However, be-
cause there are complications associated with the use of wafers, including 
infection, swelling, need for removal, and impairment of wound healing, they 
are not used routinely at most centers [81,82,80]. 
After first-line treatment, virtually all glioblastoma patients experience di-
sease progression after a median progression free survival of 7 to 10 months 
[83]. Salvage treatments include surgical re-resection, re-irradiation and chemo-
therapy (bevacizumab, TMZ rechallenge, carmustine, lomustine, carboplatin, 
irinotecan) [9,84–86]. Unfortunately, none of the available salvage treatments 
has clearly shown improved survival and likely only benefit in selected patients. 
Treatment choices should be therefore individualized, and clinical trials strongly 
considered. 
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2. INTRODUCTION TO THE STUDY 
 
Since 1978, local radiotherapy, administered after debulking surgery, has been a 
mainstay of standard treatment of GBM patients [79]. Although radiotherapy 
results in excellent local control and cure rates in most solid tumors [87], the 
efficacy of this treatment modality in GBM is extremely limited, resulting only 
in disease stabilization for a few months [79,80,7]. Almost all GBM patients 
(99%) develop fast disease progression and tumor recurrence within or imme-
diately adjacent to the high-dose radiation (60 Gy) volumes [88,89], whereas 
local recurrences are also described after very high doses such as 90 Gy [90]. 
Therefore, GBM, by nature one of the most radioresistant tumors, represents a 
major challenge in neuro-oncology.   
Detailed information about molecular mechanisms of radioresistance of 
GBM is not known. The basis of radioresistance may involve many tumor cell 
and surrounding microenvironment processes, including changes in growth 
factors and their receptors, different signaling and apoptotic pathways and DNA 
repair mechanisms [91–95]. Since there is an urgent need for new treatment 
strategies to improve the chance of survival for the patients of this fast-killing 
disease, precise knowledge about these resistance mechanisms is of great 
importance.  
 
 
2.1. PARP-1 and DNA-PK 
Radiotherapy causes a variety of DNA lesions, including single-strand brakes 
(SSB) and double-strand brakes (DSB) [96]. The lethal lesion is an unrepaired 
or misrepaired DSB produced as part of a complex lesion [97]. 
PARP-1 (Poly(ADP-ribose) polymerase 1) is an enzyme of PARP super-
family that is responsible for most of PARP activity [98]. The most well-known 
role of PARP-1 is the detection of SSB [99]. After binding to radiation-induced 
SSB (damage detection), activated PARP recruits repair enzymes (X-ray repair 
cross-complementing group 1, DNA polymerase-β, DNA ligase III) that are 
involved in base excision repair (BER) pathway. Recruited enzymes process 
broken DNA ends, synthesize missing DNA and seal the gap in DNA [100, 
101].  
DNA-PK (DNA-dependent protein kinase) plays an important role in DNA 
DSB repair by nonhomologous end joining (NHEJ) pathway [102]. DNA-PK is 
a kinase that binds to DNA DSB, phosphorylates, and activates DNA-binding 
proteins (X-ray repair cross-complementing protein 4, DNA ligase IV) [103]. 
Due to interaction of these enzymes, double strand break ends are directly 
ligated [103,104]. Since DNA repair enzyme inhibitors enhance the cytotoxic 
effects of DNA-damaging agents (radiation, chemotherapy), their role in cancer 
therapy is increasingly explored [105]. 
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2.2. CD133 
According to the brain tumor cancer stem cell model, a subpopulation of cancer 
cells possesses the capacity of self-renewal, tumor formation and the capability 
to form progeny with a more restricted fate [106]. In GBM, several stem cell 
candidate markers have been explored, however, out of these, CD133 is the 
most studied [93,107].  
CD133 is a transmembrane glycoprotein which is expressed in different type 
of progenitor cells, including hematopoietic stem cells. CD133+ GBM cells are 
considered stem cells because of their ability to self-renew, differentiate and to 
initiate tumor formation in vivo [108]. An injection of as few as 100 CD133+ 
cells has been shown to produce a tumor that could be serially transplanted and 
resembled phenotypically the patient’s original tumor [108]. 
Previous in vitro and in vivo studies have proposed that CD133+ tumor cells 
represent the cellular population that confers GBM radioresistance and could 
therefore be the source of tumor recurrence after radiation [109].  
 
 
2.3. CD63 
Radioresistance of GBM involves tumor-cell related changes, as well as 
changes that occur in tumor surrounding microenvironment. It has been 
reported that both constituents of tumor microenvironment, inflammatory and 
immune response markers are expressed in GBM [110,111]. Nevertheless, their 
exact role and impact on radiotherapy efficacy is not known. 
CD63 is a lysosomal glycoprotein that is expressed on activated platelets, 
monocytes, macrophages, as well as on granulocytes, T-cells and B-cells [112]. 
Therefore, CD63 represents one of the markers of inflammation and immune 
response that might influence tumor micromilieu and thereby cancer cells.   
 
 
2.4. ANGIOGENESIS, VEGFR-2 
GBM is one of the most angiogenic tumors. Therefore, in recent years, the inhi-
bition of tumor angiogenesis has been an extremely attractive and dominating 
experimental therapeutic strategy in neuro-oncology [113,114]. 
In GBM, at least five mechanisms by which tumors achieve neovascula-
rization have been described: vascular co-option, angiogenesis, vasculogenesis, 
vascular mimicry, and glioblastoma-endothelial cell transdifferentiation [115]. 
Out of these, angiogenesis and vasculogenesis have been most extensively 
studied and described. During angiogenesis, blood vessels arise from sprouting 
and proliferation of endothelial cells from pre-existing vascular network, 
whereas in vasculogenesis, de novo blood vessels are formed through coloni-
zation of circulating bone marrow-derived endothelial progenitor cells that are 
recruited to the tumor [115]. Both previously mentioned mechanisms of neo-
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vascularization are largely regulated via vascular endothelial growth factor 
(VEGF) and its receptor 2 (VEGFR-2) [116]. 
Downstream effects of VEGFR-2 activation in the vascular endothelium 
include cell proliferation, migration, permeability and survival, resulting in neo-
vascularization processes, such as angiogenesis and vasculogenesis [116]. Con-
sequently, this receptor has been very attractive target in the development of 
antiangiogenic drugs (e.g. bevacizumab, sunitinib, sorafenib, vatalanib, van-
detanib, recentin, cediranib) [116]. Unfortunately, a number of these antiangio-
genic drugs (vandetanib, cediranib, sorafenib, sunitinib) have failed to show 
clinical efficacy in different phases of clinical trials both in newly diagnosed 
and recurrent glioblastoma [117–121]. Moreover, the most advanced antiangio-
genic drug in glioblastoma – bevacizumab – did not get approval from The 
European Medicines Agency Committee for Medicinal Products for Human Use 
(CHMP) due to the lack of clinically relevant efficacy [122,123]. All these 
negative trials have caused a lot of frustration since the results do not coin-
cidence with the initial expectations. The reasons of the lack of significant 
clinical efficacy of antiangiogenig drugs, however, are not fully elucidated. 
It has been shown that tumor microenvironment influences GBM treatment 
outcome [95]. Whether inflammatory tumor microenvironment, which is one of 
the characteristic histological features of GBM, affects the expression of 
VEGFR-2 is not clear. 
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3. AIMS OF THE STUDY 
 
The general aim of the study was to identify possibilities to improve the effi-
cacy of radiotherapy and chemotherapy in patients with GBM. 
 
Accordingly, the specific aims were: 
1. To explore, whether higher tumor levels of DNA repair enzymes (PARP-1, 
DNA-PK) contribute to worse treatment results of GBM patients after post-
operative radiotherapy. 
2. To test, whether higher proportion of CD133+ GBM cells (stem cell popu-
lation) contributes to worse treatment results after postoperative radiothe-
rapy. 
3. To evaluate the impact of tumor infiltrating CD63+ inflammatory and 
immune cells on radiotherapy treatment response and survival of GBM 
patients. 
4. To evaluate the impact of tumor microenvironment, particularly inflam-
matory reaction, on the expression of VEGFR-2 – one of the main targets of 
antiangiogenic drugs. 
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4. MATERIAL AND METHODS 
 
4.1. PATIENTS  
All the studies were approved by the Research Ethics Committee of the Univer-
sity of Tartu, Estonia. 
Between January 2006 and December 2008, maximum of 42 patients with 
GBM were treated with postoperative three-dimensional (3D) radiotherapy at 
Tartu University Hospital or North Estonia Medical Centre. Characteristics of 
patients are listed in table 1.  
 
 
Table 1: Characteristics of 42 patients with glioblastoma multiforme 
 
Variable 
 
No of patients (n=42) 
 
Percentage (%) 
Gender 
 Male 
 Female 
Age, years (mean)* 
Radiotherapy dose (mean) 
Chemotherapy** 
 No 
 Yes 
 
23 
19 
 
19–77 (57 years) 
30–60 Gy (54 Gy) 
16 
26 
 
55% 
45% 
 
 
 
38% 
62% 
* Age at the time of operation 
** Used for recurrent disease 
 
 
 
4.2. TREATMENT PLANNING AND  
TREATMENT PARAMETERS 
Treatment planning was performed using CT/MRI scans and TPS XiO CMS 
treatment planning system. The gross tumor volume (GTV) encompassed the 
resection cavity and any residual tumor. A 2–3 cm margin was added to create 
clinical target volume (CTV). Critical tissues were spared (brainstem, chiasma). 
For planned target volume (PTV), 0.5 cm margin was included. Treatments 
were performed using linear accelerators (30–60 Gy in 2.0 Gy fractions; mean 
dose 54 Gy). The prescribed dose was normalized to 100% at the isocenter and 
PTV was covered by 95% isodose surface (ICRU Report 50). None of the pa-
tients received concomitant and adjuvant chemotherapy with TMZ (available 
since 2010). However, for recurrent disease, 26 patients received chemotherapy 
with lomustine (CCNU). 
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4.3. HISTOLOGY  
Surgically excised GBM specimens were immediately fixed in the buffered 
10% formaline (pH 7.4) for 24 hours and subsequently embedded into paraffin 
wax as routinely performed. From the resulting tissue blocks, serial paraffin 
sections of 4 µm were cut and placed on glass slides for standard hematoxylin-
eosin (H&E) stain and immunohistochemistry. The diagnosis of GBM was con-
firmed in the H&E stained slides by 2 independent pathologists. 
 
 
4.4. IMMUNOHISTOCHEMISTRY 
Additional sections were cut from archived paraffin blocks and stained 
according to standard immunohistochemistry (IHC) protocol. 
For immunostaining, solutions and buffers provided by DAKO (Hamburg, 
Germany) were used. The sections were deparaffinized and incubated in the 
target retrieval solution (pH 9.0) in the 96°C thermostated water bath for 40 min 
and afterwards in peroxidase blocking solution for 5 min at room temperature. 
Subsequently, the tissue sections were incubated with the specific antibodies at 
room temperature for 1 hour in humid conditions. After several washings, the 
antigen-antibody complex was visualized by using DAKO REALTM EnVision 
Detection System, Peroxidase/DAB+, Rabbit/Mouse. Diaminobenzidine was 
used as chromogen. Slides were counterstained with hematoxyline, dehydrated 
and coverslipped for light microscopy.  
Characteristics of primary antibodies used for immunohistochemical staining 
are listed in table 2.  
 
 
Table 2: Characteristics of primary antibodies used for immunohistochemical staining 
Primary antibody Supplier Catalogue number Dilution 
anti-PARP-1 antibody 
anti-DNA-PKcs antibody 
anti-CD133 antibody 
anti-CD63 antibody 
anti-ICAM-1 antibody 
anti-VEGFR-2 antibody 
Bethyl Laboratories 
Bethyl Laboratories 
Biorbyt Ltd. 
Santa Cruz Biotechnology, Inc. 
Santa Cruz Biotechnology, Inc. 
Santa Cruz Biotechnology, Inc. 
#IHC-00279 
#IHC-00044 
#orb18124 
#sc-5275 
#sc-8439 
#sc-6251 
1:250 
1:250 
1:50 
1:150 
1:100 
1:100 
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4.5. EVALUATION AND SCORING  
Evaluation and scoring of slides are shortly described in table 3. 
 
 
Table 3: Evaluation and scoring of slides 
 
Parameter 
 
Staining 
 
Scoring 
 
Description 
Inflammatory 
reaction 
H&E 
 
Arbitrary score 1–3
 
1= weak inflammation 
2= moderate inflammation 
3= strong inflammation 
Necrosis H&E Percentage (%) Overall extent of necrosis 
PARP-1 staining 
intensity 
(tumor cells) 
 
IHC 
 
Arbitrary score 0–3
 
0= no staining 
1= weak staining intensity 
2= moderate staining intensity 
3= strong staining intensity 
DNA-PK staining 
intensity 
(tumor cells) 
 
IHC 
 
Arbitrary score 0–3
 
0= no staining 
1= weak staining intensity 
2= moderate staining intensity 
3= strong staining intensity 
CD133+ cells 
(stem like cells) 
IHC 
 
Percentage (%) 
 
Proportion of CD133+ cells per 
microscopic field 
CD63+ cells 
(inflammatory and 
immune cells) 
IHC 
 
Number  
 
Number of CD63+ cells per 
microscopic field 
ICAM-1 
(tissue expression) 
IHC 
 
Optical density 
(0–255) 
Pixel values measured by digital 
image analysis 
VEGFR-2 staining 
intensity 
(endothelial) 
 
IHC 
 
Arbitrary score 0–3
 
0= no staining 
1= weak staining intensity 
2= moderate staining intensity 
3= strong staining intensity 
 
 
 
4.5.1. Histology 
H&E stained sections were used to assess two parameters, both determined by 
an experienced pathologist.  
First, the overall extent of necrosis was assessed. For this, the whole section 
of tumor tissue was evaluated and overall proportion (%) of necrosis estimated.   
Afterwards, overall extent of inflammatory reaction was determined. This 
was based on typical visual appearance of inflammation, including presence of 
edema and inflammatory cell infiltration. For the evaluation, an arbitrary score 
ranging from 1 to 3 was applied (1= weak, 2= moderate, 3= strong inflamma-
tory reaction).  
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4.5.2. Immunohistochemistry 
The evaluation and scoring of immunohistochemically stained slides were 
carried out in a blinded fashion.  
 
 
4.5.2.1. PARP-1 and DNA-PK 
The evaluation and scoring of slides were carried out in 5 randomly taken 
microscopic fields at a magnification of × 40. Scoring was performed twice by 
one researcher. 
Immunohistochemical staining intensities of PARP-1 and DNA-PK were 
quantified using an arbitrary score ranging from 0 to 3 (0= no staining; 1= 
weak, 2= moderate, 3= strong staining intensity). GBM tissue displayed mainly 
cytoplasmic expression of PARP-1 and nuclear expression of DNA-PK. There-
fore, for PARP-1 cytoplasmic and for DNA-PK nuclear staining intensities were 
determined. Staining intensities of PARP-1 and DNA-PK positive cells were 
scored for each of five microscopic fields (excluding negative cells and necrotic 
areas). For individual values, the mean of 10 scores (2 x 5 fields) was 
calculated.  
Individual means were used to determine group mean and median values. 
According to median values of PARP-1 and DNA-PK, patients were divided 
into subgroups ≥ median (equal and more than median) and < median (less than 
median). These subgroups were used in survival analysis. 
 
 
4.5.2.2. CD133 
The proportion of CD133-positive (CD133+) cells was determined in 6 random-
ly taken microscopic fields at a magnification of × 40. The evaluation and 
scoring of slides were carried out by 2 independent researchers. 
For individual values, the mean proportion of CD133+ cells (%) was 
determined in 6 microscopic fields. These values were used to evaluate the 
correlation between the assessments of 2 independent researchers. Afterwards, 
the mean proportion of CD133+ cells in 12 microscopic fields (2 × 6 fields) was 
calculated. The proportion of CD133+ GBM cells was determined in areas with 
vital tumor tissue (excluding necrotic areas).  
Individual means of CD133+ cell proportions were used to determine group 
mean and median values. According to the median value of CD133+ pro-
portions, patients were divided into subgroups ≥ median (equal and more than 
median) and < median (less than median). These subgroups were used in 
survival analysis. 
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4.5.2.3. CD63 
The evaluation and scoring of slides were carried out in 5 randomly taken 
microscopic fields at a magnification of × 40. The evaluation was carried out by 
2 independent researchers. 
For individual values, the mean number of tumor infiltrating CD63-positive 
(CD63+) inflammatory and immune cells per microscopic field was determined 
in 5 microscopic fields. These values were used to evaluate the correlation 
between the assessments of 2 independent researchers. Afterwards, the mean 
number of tumor infiltrating CD63+ cells in 10 microscopic fields (2 × 5 fields) 
was calculated. The number of CD63+ cells was determined in areas with vital 
tumor tissue (excluding necrotic areas).  
Individual means of CD63+ inflammatory and immune cell numbers were 
used to determine group mean and median values. According to the median 
value of CD63+ numbers, patients were divided into subgroups ≥ median (equal 
and more than median) and < median (less than median). These groups were 
used in survival analysis. 
 
4.5.2.4. ICAM-1 
For intercellular adhesion molecule 1 (ICAM-1) expression, digital IHC image 
analysis was performed. Tissue expression of ICAM-1 was determined at a 
magnification of × 10. 
IHC digital image analysis was carried out in 6 selected images from each 
slide by using the freeware program ImageJ. The brown-colored area, occupied 
by the immunohistochemical reaction was selected by the color threshold 
filtering tool to substract the hematoxylin-stained areas at the background. Then 
the images were converted to the greyscale and the optical density by the area 
method was measured in pixel values ranging from 0–255. Value 0 represents 
the lightest shade of the color while 255 the darkest shade of the color in the 
image.  
 
4.5.2.5. VEGFR-2 
The evaluation and scoring of slides were carried out in 5 randomly taken 
microscopic fields at a magnification of × 40. The evaluation was performed by 
2 independent researchers. 
For VEGFR-2 expression, two parameters were assessed. First, the number 
of VEGFR-2 positive (VEGFR-2+) blood vessels per microscopic field was 
determined. Additionally, endothelial VEGFR-2 staining intensity was 
evaluated using an arbitrary score ranging from 0 to 3 (0= no staining; 1= weak, 
2= moderate, 3= strong staining intensity).  
For individual values, both parameters were determined in 5 microscopic 
fields. These values were used to evaluate the correlation between the assess-
ments of 2 independent researchers. Afterwards, the mean number of VEGFR-
2+ blood vessels and VEGFR-2 staining intensity in 10 microscopic fields (2 × 
25 
5 fields) were calculated. All VEGFR-2 parameters were determined in areas 
with vital tumor tissue (excluding necrotic areas). 
 
 
4.6. STATISTICAL ANALYSIS  
The SPSS statistical software was used to calculate individual means, group 
means, and standard deviations of the mean as well as median values. In 
addition, the author used Pearson correlation analysis. 
The magnitude of pre-irradiation PARP-1 and DNA-PK expression, the pro-
portion CD133+ GBM cells and the number of tumor infiltrating CD63+ 
inflammatory and immune cells were correlated with the overall survival that 
was defined as the period from the date of operation to the date of death 
resulting from GBM or to the date of last analysis. Survival curves were created 
using the Kaplan-Meier method and differences between the groups were 
compared using the log-rank test. Multivariate analysis was performed using the 
Cox proportional hazards model. Due to small number of patients, maximum of 
4 variables were included into multivariate analysis. A p-value <0.05 was 
regarded statistically significant. 
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5. RESULTS 
 
5.1. PARP-1 and DNA-PK (Paper I) 
5.1.1. Expression of PARP-1 and DNA-PK 
In a normal brain, a weak constitutive expression of PARP-1 and DNA-PK was 
seen. GBM tissue displayed various levels of PARP-1 (mainly cytoplasmic) and 
DNA-PK (nuclear) expression. Figure 3 illustrates low (score 1) and high (score 
3) expression of PARP-1 and DNA-PK in the tumor tissue.  
 
 
 
 
Figure 3. Expression of PARP-1 and DNA-PK in GBM 
Photos illustrate PARP-1 and DNA-PK immunohistochemical staining intensities in 
GBM tissue. A: weak cytoplasmic (score 1) staining intensity of PARP-1, B: strong 
cytoplasmic (score 3) staining intensity of PARP-1, C: weak nuclear (score 1) staining 
intensity of DNA-PK, D: strong nuclear (score 3) staining intensity of DNA-PK. 
 
 
Among individual GBM patients, the magnitude of PARP-1 immunoreactivity 
in the tumor tissue ranged from 1.2 to 2.8 (individual means). The mean and 
median values of PARP-1 expression of the entire study group were 1.96±0.50 
(mean±SD) and 2.0 respectively. There were slightly more patients with high 
(≥median) expression levels of PARP-1 (56%) in the study group. Individual 
levels of DNA-PK expression ranged from 0.8 to 2.8 (individual means). The 
27 
mean and median values of DNA-PK expression of the entire study group were 
2.02±0.49 (mean±SD) and 2.0, respectively. Similarly to PARP-1, there were 
more patients with high (≥median) expression levels of DNA-PK (65%) in the 
whole study group. 
 
 
5.1.2. Correlation of tumor PARP-1 and DNA-PK expression with 
overall survival 
Thirty two patients had died by the time of analysis. The median overall 
survival of the whole study group was 10.0 months (95% CI 8.1–11.9). The 
overall survival among the patients with low (<median) and high (≥median) 
expression levels of PARP-1 is represented in figure 4. The median survival of 
the patients with low and high tumor PARP-1 levels did not differ significantly, 
being 12.0 months (95% CI 8.3–15.7) and 10.0 months (95% CI 7.9–12.1) 
respectively (p=0.93). In contrast, figure 5 illustrates significant overall survival 
difference between the patients with low (<median) and high (≥median) 
expression levels of DNA-PK. The median survival of the patients with low and 
high tumor DNA-PK levels were 13.0 months (95% CI 10.7–15.3) and 9.0 
months (95% CI 7.2–10.8) respectively (p=0.02).  
DNA-PK expression (HR 3.9, 95% CI 1.5–10.7, p=0.01) and Karnofsky 
Performance Score (KPS; HR 3.3, 95% CI 1.4–8.4, p=0.01) emerged as the 
significant independent prognostic factors for overall survival in the multi-
variate analysis (Table 4).  
 
 
Table 4: Multivariate analysis for overall survival 
 Overall survival 
Variable  p HR (95% CI) 
 
DNA-PK* 
PARP-1* 
Chemotherapy 
Karnofsky performance score 
 
IHC range 0.8–2.8 
IHC range 1.2–2.8 
yes vs no 
<70% vs ≥70% 
 
0.01 
0.12 
0.89 
0.01 
 
3.9 [1.5–10.7] 
0.5 [0.2–1.2] 
1.1 [0.4–2.6] 
3.3 [1.4–8.4] 
 
*Continuous variable; IHC – Immunohistochemical staining intensity; HR – Hazard 
Ratio;  
CI – Confidence Interval 
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Figure 4. Kaplan-Meier analysis of overall survival according to PARP-1 expression 
The median survival of patients with low and high tumor PARP-1 levels did not differ 
(p=0.961). 
 
 
 
 
Figure 5. Kaplan-Meier analysis of overall survival according to DNA-PK expression 
The median survival of patients with low and high tumor DNA-PK levels differed 
significantly (p=0.016). The median survival of the patients with low and high tumor 
DNA-PK levels were 13.0 months (95% CI 10.7–15.3) and 9.0 months (95% CI 7.2–
10.8) respectively.  
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5.2. CD 133 (Paper II) 
5.2.1. Proportion of CD133+ GBM cells 
In GBM tumor samples, the proportion of CD133+ cells varied greatly between 
patients. Figure 6 illustrates low (<median) and high (≥median) CD133+ cell 
proportions in the tumor tissue.  
 
 
 
 
Figure 6. CD133+ stem cells in GBM  
Photos illustrate different proportions of CD133+ stem cells (A: low, B: high) in GBM 
tissue. 
 
 
The proportion of CD133+ GBM stem cells was determined by 2 independent 
researchers whose results were in good accordance (R=0.8, p<0.0001).  
Among individual GBM patients, the proportion of CD133+ stem cells in 
tumor tissue ranged from 0.5% to 82% (individual means). Mean and median 
proportions of CD133+ cells of the entire study group were 33%±24% (mean± 
SD) and 28% respectively. According to individual values, patients were di-
vided into two groups: patients with low (<median) and high (≥median) 
proportion of CD133+ GBM cells. Groups were sufficiently balanced, since 
there were 48% of patients with low (<median) and 52% of patients with high 
(≥median) proportion of CD133+ cells.  
Additionally to IHC the overall proportion of necrosis (%) was determined 
in haematoxylin-eosin stained tissue sections. The mean proportion of necrosis 
of the entire study group was 38%±31% (mean±SD). Correlation analysis, 
based on the individual values, revealed a significant association between the 
proportion of stem-cells and the percentage of necrosis (R=0.5, p<0.01). 
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5.2.2. Correlation of CD133+GBM cell proportion with  
overall survival 
Forty patients had died by the time of analysis. The median overall survival of 
the whole study group was 10.0 months (95% CI 9.0–11.0). Figure 7 illustrates 
the overall survival among patients with low and high proportion of CD133+ 
GBM cells. Their survival times clearly depended on the proportion of CD133+ 
cells (log rank test, p=0.02). Median survival times for patients with low 
(<median) and high (≥median) proportion of CD133+ cells were 9.0 months 
(95% CI 7.6–10.5) and 12.0 months (95% CI 9.3–14.7) respectively. 
 
 
 
 
Figure 7. Kaplan-Meier analysis of overall survival according to CD133+ GBM stem 
cell proportions 
The median survival of patients with low and high proportions of CD133+ stem cells 
differed significantly (p=0.02). Median survival times for patients with low (<median) 
and high (≥median) proportion of CD133+ cells were 9.0 months (95% CI 7.6–10.5) 
and 12.0 months (95% CI 9.3–14.7) respectively. 
 
 
In multivariate analysis (table 5), the proportion of CD133+ cells (HR 2.0, 95% 
CI 1.0–3.8, p=0.04) and Karnofsky Performance Score (HR 2.2, 95% CI 1.0–
4.8, p=0.04) emerged as significant independent prognostic factors for overall 
survival. 
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Table 5: Multivariate analysis for overall survival 
 Overall survival 
Variable  p HR (95% CI) 
 
CD133+ 
Radiotherapy dose* 
Chemotherapy 
Karnofsky performance score 
 
<median vs ≥median 
range 30–60 Gy 
yes vs no 
<70% vs ≥70% 
 
0.04 
0.24 
0.75 
0.04 
 
2.0 [1.0–3.8] 
1.0 [0.9–1.0] 
1.1 [0.5–2.4] 
2.2 [1.0–4.8] 
* Continuous variable; HR- Hazard Ratio; CI- Confidence Interval 
 
 
 
5.3. CD63 (Paper III) 
5.3.1. Numbers of tumor infiltrating CD63+ inflammatory and  
immune cells 
In GBM tumor samples, the numbers of CD63+ cells varied greatly between pa-
tients. Figure 8 illustrates low (<median) and high (≥median) CD63+ inflamma-
tory and immune cell numbers in tumor tissue.  
 
 
 
 
Figure 8. CD63+ inflammatory and immune cells in GBM  
Photos illustrate different numbers of CD63+ inflammatory and immune cells (A: low, 
B: high) in GBM tissue. 
 
 
The numbers of CD63+ cells was determined by 2 independent researchers 
whose results were in good accordance (R=0.8, p<0.0001).  
Among individual GBM patients, the numbers of CD63+ cells per micro-
scopic field ranged from 10.3 to 134.5 (individual means). The mean and 
median numbers of CD63+ inflammatory and immune cells of the entire study 
group were 45.3±27.2 (mean±SD) and 39.6, respectively. According to indivi-
dual values, patients were divided into two groups: patients with low (<median) 
and high (≥median) numbers of CD63+ tumor infiltrating cells. Groups were 
balanced, since there were 50% of patients with low (<median) and 50% of 
patients with high (≥median) numbers of CD63+ cells.  
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In addition to immunohistochemistry, the overall proportion of necrosis (%) 
was determined in haematoxylin-eosin stained tissue sections by an experienced 
pathologist. The mean proportion of necrosis of the entire study group was 
38%±31% (mean±SD). Correlation analysis, based on individual values, 
revealed a significant association between the numbers of CD63+ tumor 
infiltrating inflammatory and immune cells and the percentage of necrosis 
(R=0.5, p=0.004). 
 
 
5.3.2. Correlation of tumor infiltrating CD63+ inflammatory and 
immune cell numbers with overall survival 
Thirty eight patients had died by the time of analysis. The median overall 
survival of the whole study group was 10.0 months (95% CI 9.0–11.0). Figure 9 
illustrates the overall survival among patients with low and high numbers of 
CD63+ tumor infiltrating inflammatory and immune cells. The survival times 
clearly depended on the number of CD63+ cells (log rank test, p=0.003). 
Median survival times for patients with low (<median) and high (≥median) 
numbers of CD63+ cells were 9.0 months (95% CI 8.1–9.9) and 12.0 months 
(95% CI 8.5–15.5), respectively. 
 
 
 
 
Figure 9. Kaplan-Meier analysis of overall survival according to CD63+ inflammatory 
and immune cell numbers 
The median survival of patients with low and high numbers of CD63+ inflammatory 
and immune cells differed significantly (p=0.003). Median survival times for patients 
with low (<median) and high (≥median) numbers of CD63+ cells were 9.0 months 
(95% CI 8.1–9.9) and 12.0 months (95% CI 8.5–15.5) respectively. 
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In multivariate analysis (Table 6), the number of CD63+ tumor infiltrating 
inflamematory and immune cells (HR 2.4, 95% CI 1.2–5.1, p=0.02) emerged as 
significant independent prognostic factor for OS.  
 
 
Table 6: Multivariate analysis for overall survival 
 Overall survival 
Variable  p HR (95% CI) 
 
CD63+ 
Radiotherapy dose* 
Chemotherapy 
Karnofsky performance score 
 
<median vs ≥median 
range 40–60 Gy 
yes vs no 
<70% vs ≥70% 
 
0.02 
0.59 
0.66 
0.13 
 
2.4  [1.2–5.1] 
1.0  [0.9–1.1] 
1.2  [0.6–2.5] 
1.9  [0.8–4.5] 
* Continuous variable; HR- Hazard Ratio; CI- Confidence Interval 
 
 
 
5.4. Inflammation, ICAM-1 and VEGFR-2 (Paper IV) 
5.4.1. Inflammation and ICAM-1 
In individual GBM samples, the extent of inflammation varied, being in the 
whole group 1.9±0.7 (mean±SD). Figure 10 represents GBM tissues with weak 
(A), moderate (B), and strong (C) visual inflammatory reaction.  
 
 
 
 
 
Figure 10. Inflammatory reaction in GBM 
Photos illustrate GBM tissues with inflammatory reaction. A: weak (score 1) 
inflammation, B: moderate (score 2) inflammation, C: strong (score 3) inflammation. 
Note different numbers of tumor infiltrating inflammatory cells. 
 
 
Similarly, individual optical densities of ICAM-1 in GBM tissue varied, ranging 
from to 17.6 to 154.9 pixel values. Group mean optical density of ICAM-1 was 
57,0±27.1 (mean±SD). Figure 11 illustrates GBM tissues with weak (A), 
moderate (B), and strong (C) optical density of ICAM-1. 
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Figure 11. ICAM-1 expression in GBM 
Photos illustrate GBM tissues with different extent of ICAM-1 expression. A: weak 
optical density, B: moderate optical density, C: strong optical density. 
 
5.4.2. VEGFR-2 
VEGFR-2 parameters were determined by 2 independent researchers whose 
results were in good accordance (R=0.8, p<0.0001). 
In GBM tissue sections, the number of VEGFR-2+ blood vessels per micro-
scopic field and endothelial VEGFR-2 staining intensity were 6.2±2.4 
(mean±SD) and 1.2±0.8 (mean±SD) respectively. Figure 12 illustrates GBM 
tissues with weak (A), moderate (B), and strong (C) expression level of 
VEGFR-2 in tumor blood vessels.  
 
 
 
 
Figure 12. VEGFR-2 expression in GBM blood vessels 
Photos illustrate GBM tissues with different endothelial staining intensities of VEGFR-
2 in blood vessels. A: weak (score 1) staining intensity, B: moderate (score 2) staining 
intensity, C: strong (score 3) staining intensity. Note also different numbers of VEGFR-
2+ blood vessels. 
 
 
5.4.3. Correlation of VEGFR-2 expression with  
inflammation and ICAM-1 
The results of correlation analysis are described in table 7. A positive as-
sociation was found between the extent of visual inflammation and VEGFR-2 
staining intensity (R=0.4, p=0.005). Moreover, VEGFR-2 staining intensity 
correlated with the expression level (optical density) of tissue ICAM-1 (R=0.4, 
p=0.026). Additionally, there was a trend toward significant association 
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between the number of VEGFR-2 positive blood vessels and VEGFR-2 staining 
intensity in GBM tissue (R=0.3, p=0.065). 
 
 
Table 7: Correlation of VEGFR-2 expression with inflammation and ICAM-1* 
 
Correlations 
 
p value 
 
Visual inflammatory reaction and VEGFR-2 staining intensity 
Tissue ICAM-1 expression and VEGFR-2 staining intensity 
The number of VEGFR-2+ blood vessels and VEGFR-2 staining 
intensity 
 
p=0.005 
p=0.026 
p=0.065 
* Bivariate Pearson correlation test 
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6. DISCUSSION 
 
6.1. PARP-1 and DNA-PK 
In the present study, we assessed 2 DNA-repair enzymes (PARP-1, DNA-PK) 
in GBM tissue before standard radiotherapy. Our study revealed a weak consti-
tutive expression of PARP-1 and DNA-PK in normal brain tissue. Similarly, 
constitutive expression of PARP-1 and DNA-PK within normal brain has been 
documented in previous human studies [124,125]. A primary function of PARP-
1 and DNA-PK under basal condition is the detection of DNA damage and the 
facilitation of DNA repair to maintain genomic integrity [126,127]. Similarly to 
our findings, the high expression of DNA repair enzymes in GBM tissue has 
been described in other studies [125,128].   
In the present study, the median survival of the entire study group was 10.0 
months. This is in a good accordance with previous studies where postoperative 
radiotherapy has resulted in median survival of 9.0–11.6 months [79,129,80]. 
Since GBM patients had different tumor levels of PARP-1 and DNA-PK, we 
looked whether differences in protein expression influence the treatment 
outcome. Our study showed that survival did not depend on PARP-1 expression 
in tumor tissue, since median survival of GBM patients with high or low levels 
of PARP-1 did not differ. In contrast, survival was significantly influenced by 
the expression level of DNA-PK, showing much shorter median survival of 
patients with high tumor levels (9.0 months) compared to patients with low 
levels (13.0 months). Moreover, multivariate analysis showed that next to the 
well-established prognostic factor KPS [130], DNA-PK expression emerged as 
a significant independent predictor for overall survival. This suggests that GBM 
patients with high tumor levels of DNA-PK are more resistant and respond less 
to standard radiotherapy. 
No clinical studies have been published which compare treatment outcome 
of GBM patients after radiotherapy depending on tumor PARP-1 and DNA-PK 
expression levels. Therefore, the data of the present study cannot be compared 
with similar studies. In spite of that, there are some preclinical studies where 
inhibition of these DNA repair enzymes (resulting in low levels of these 
enzymes) has been tested in GBM cell cultures. The effect of PARP-1 inhibitor 
Olaparib in combination with radiotherapy has been evaluated in four GBM cell 
lines (T98G, U373-MG, UVW, U87-MG) [131]. In three GBM cell lines, 
decrease in surviving fraction of tumor cells, radiosensitization and delayed 
repair of radiation-induced DNA-brakes were seen. However, in U87-MG cell 
line, Olaparib had no effect on radiation sensitivity in 2 independent studies 
[131,132]. This shows that the inhibition of PARP-1 might be insufficient to 
increase the radiosensitivity of GBM, which is also suggested in our study.  
Previous in vitro studies have demonstrated that DNA-PK-deficient cell line 
(MO59J) is approximately 30-fold more sensitive to radiation than DNA-PK-
proficient cell line (MO59K) [133]. Moreover, specific DNA-PK inhibitors 
SU11752 and wortmannin have demonstrated to sensitize GBM cells (MO59K) 
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to radiotherapy [134]. Interestingly, SU11752 alone did not affect GBM cell 
survival. However, in combination, SU11752 sensitized cells fivefold to 
ionizing radiation at 2 Gy with even more pronounced effect at higher radiation 
doses. Most recent in vitro study confirmed that novel DNA-PK inhibitor 
NU7741 increased the cytotoxicity of irradiation by twofold in MO59-Fus-1 
cells (DNA-PK-proficient) whereas it had no effect on MO59J cells [135]. 
NU7741 decreased the repair of radiation-induced DSB and inhibited also 
homologous recombination activity (assessed by Rad51 foci) in a DNA-PK 
dependent manner. This shows that there is a potential cross talk of DNA-PK 
with another important DNA repair pathway – homologous recombination. 
Additionally, specific inhibition of DNA-PK with short hairpin RNA (shRNA) 
has been shown to radiosensitize glioma-initiating cells [136].  
Since only high expression of DNA-PK correlated with poor survival of 
GBM patients, the repair of DSB rather than SSB might have a prognostic 
value. Similarly, previous experimental studies have shown that the incidence of 
cell killing, and higher response to radiotherapy do not correlate with the 
induced number of SSB, but relates better to the incidence of DSB [15]. 
Radiotherapy has been shown to produce equivalent number of DNA lesions in 
MO59J (DNA-PK-deficient) and MO59K (DNA-PK-proficient) GBM cell lines 
[137]. Nevertheless, significant DNA damage repair was evident for MO59K 
cells with a 5.8 fold increase in relative survival, whereas MO59J GBM cells 
showed little repair capacity. More DSB were repaired by 30 min in MO59K 
cells than in MO59J cells, suggesting that deficient DSB repair may be a major 
determinant of radiosensitivity of GBM cells. 
Present study measured only baseline (preirradiation) levels of PARP-1 and 
DNA-PK expression. Due to study design, changes in these proteins that might 
occur during radiotherapy cannot be described. However, previous in vitro 
study has shown that there is a radiation-induced increase in the activity of 
PARP in glioblastoma cell line A172 [138]. Also, in MO59K cell line, both 
DNA-PK relative protein level and DNA-PK activity have been shown to 
increase in response to irradiation [139]. In contrast, there was no increase in 
DNA-PK protein level and no detectable kinase activity in DNA-PK deficient 
MO59J cells, either with or without irradiation.  
In the present study, only postoperative radiotherapy was used. However, 
radiotherapy alone is no longer standard adjuvant treatment of GBM. In 
countries with access to temozolomide, combined treatment consisting of radio-
therapy and concomitant as well as adjuvant chemotherapy (radiochemo-
therapy) is preferably used [7]. Whether tumor PARP-1 and DNA-PK expres-
sion have the prognostic value for patients treated with combined treatment 
schedule, is not clear. Nevertheless, the effect of DNA repair enzymes on 
combined treatment results is rather plausible since TMZ has been shown to 
produce DNA lesions that are substrates for base excision repair and 
homologous recombination DNA repair pathways [140,141]. In vivo, mice 
treated with combined treatment of PARP inhibitor E7016 plus radiotherapy 
and temozolomide, showed additional growth delay of six days compared with 
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the combination of radiotherapy and temozolomide [142]. Additionally, pre-
vious in vitro studies have reported that in glioblastoma cells (MO59K, 
MO59J), the sensitivity of temozolomide depends on DSB repair efficiency 
since DSB are critically involved in drug-induced apoptosis [143]. 
In conclusion, this hypothesis generating study showed that the survival of 
GBM patients receiving postoperative radiotherapy depends on the tumor 
expression of DNA-PK. Further studies are needed to clarify whether DNA-PK 
inhibitors might have a potential to radiosensitize GBM and improve the 
treatment outcome of this devastating disease.  
 
 
6.2. CD 133 
In the current study, the presence of CD133+ cells in GBM tissue was detected 
by immunohistochemical staining method. The proportion of CD133+ GBM 
stem cells was determined in surgically excised tumor tissue, i.e. prior 
radiotherapy. The study revealed wide variability in the proportion of these 
cells. Among evaluated GBM samples, there were tumors that contained only 
0.5% CD133+ GBM cells but also tissues in which the proportion of CD133+ 
cells was as high as 82%. The variability in CD133+ GBM stem cell propor-
tions has also been reported in studies of 37 and 44 consecutive GBM patients, 
where CD133 expression ranged between 0.5% and 10.0% [144,145]. However, 
in our study, somewhat higher CD133+ GBM cell proportions were detected 
(median 28%) that might be related to the use of different primary CD133 
antibody clone [146].  
Present study revealed the correlation between the proportion of CD133+ 
stem cells and the overall proportion of tissue necrosis. It is widely accepted 
that necrosis typically develops in hypoxic (low-oxygen) environments. In 
GBM, the expression of hypoxia markers (CAIX and HIF-1α) has been shown 
to be especially high in tumor regions containing 10% to 45% necrosis of total 
area [147]. Additionally, it has been reported that tumor-initiating CD133+ 
GBM stem cells are preferentially expanded in hypoxic conditions [147,148]. 
Therefore, hypoxia might have also influenced the proportion of CD133+ GBM 
cells in the present study. 
Additionally to the determination of CD133+ cell proportions, tumor CD133 
expression levels were correlated with GBM patients overall survival. The 
median survival of the entire study group was 10.0 months. However, the 
survival time clearly depended on the proportion of CD133+ GBM stem cells. 
Median survival times for patients with low (<median) and high (≥median) 
proportion of CD133+ cells were 9.0 months and 12.0 months respectively. In 
contrast to what was expected, significantly longer survival times after 
postoperative radiotherapy were achieved in patients with higher stem cell 
proportion. To the knowledge of authors, there are no other clinical studies that 
would have evaluated the prognostic significance of CD133 expression after 
GBM radiotherapy. Nevertheless, clinical series that have used radiochemo-
39 
therapy (radiotherapy and concomitant plus adjuvant TMZ), which currently 
represents standard-of-care treatment for GBM, have shown opposite results. In 
clinical study of 44 GBM patients, the CD133+ tumor cell proportion of ≥2% 
negatively correlated with overall survival [144]. Additionally, mRNA expres-
sion analysis in 48 GBM patients showed that high sample CD133 mRNA 
expression was a significant prognostic factor for adverse overall survival 
independent of the extent of resection and O(6)-methylguanine-DNA methyl-
transferase (MGMT) gene methylation status [149]. These opposite results may 
be related to other treatment protocol (radiochemotherapy), different primary 
antibody used for CD133 immunohistochemical detection, as well as to the fact 
that mRNA expression study samples contained up to 50% of non-tumor tissue, 
which may also contain CD133 [150]. 
Similarly to our findings, different clinical outcomes were documented in a 
study that divided GBM patients into 2 groups (CD133-low, CD133-high) 
according to CD133+ cell ratio either <3% or ≥3%, as detected by FACS 
analysis (fluorescence activated cell scanning) of primary tumor cultures. 
Namely, tumors from CD133-low GBM patients were shown to have tendency 
to be localized within the deeper structures of the brain, to show more invasive 
growth patterns and ventricle involvement, as well as relatively higher rate of 
disease progression after radiotherapy and chemotherapy [151]. Also, although 
not in primary GBM, significantly longer survival times were detected in 
recurrent GBM patients with higher proportion of CD133+ cells [145]. In 
addition, the multivariate analysis of the present study revealed that next to the 
well-established prognostic factor KPS, CD133+ GBM stem cell proportion 
emerged as a significant independent predictor for overall survival. This clearly 
suggests that GBM patients with high proportion of CD133+ tumor cells 
respond better to radiotherapy and achieve better treatment response that 
consequently result in longer survival times. 
It has been widely accepted that CD133+ GBM stem cells are especially 
radioresistant [109]. The findings of our study point toward the possibility that 
these cells might be, in contrast to what has been believed, radiosensitive. The 
radioresistant nature of CD133+ GBM stem cells has been mainly documented 
in studies that compare isolated CD133+ and CD133- GBM cell lines 
[109,152]. However, when compared to the traditional glioblastoma established 
cell lines that contain heterogeneous cell subpopulations, higher radiosensitivity 
of CD133+ GBM stem cells has been seen. It has been previously reported that 
CD133+ GBM stem cells have a reduced capacity to repair radiation-induced 
double strand brakes (DSBs), which is likely to be a major contributor to the 
relatively greater degree of radiosensitivity [153]. Therefore, the radiosensitivity 
of CD133+ GBM stem cells might be greatly underestimated. 
As mentioned earlier, a correlation between the proportion of CD133+ GBM 
stem cells and the overall proportion of tissue necrosis was found. This shows 
indirectly that also a surrounding microenvironment may contribute to the 
radiation response of GBM stem cells. Indeed, recent publications have con-
firmed this relationship. It has been demonstrated that GBM stem cells 
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irradiated in vivo within orthotopic xenografts are less susceptible to DSB 
induction and have greater capacity to repair damage as compared to same 
tumor cells irradiated under in vitro growth conditions [154]. Moreover, close 
correlation between CD133+ GBM cells and hypoxia [147], vascular structures 
[91], extracellular matrix (ECM) components [93], as well as inflammation and 
immunoregulatory markers [155] have been reported. This all shows that 
radiation response of CD133+ GBM stem cells are determined by a numerous 
known and unknown processes that can be collectively named as “micro-
environment-stem cell unit” [93]. 
In conclusion, our study showed that there is no association between higher 
proportion of stem cells and the aggressiveness of GBM. In contrast, in patients 
with higher stem cell proportion, significantly longer survival times after post-
operative radiotherapy were achieved.  
 
 
6.3. CD63 
It has been shown that both tumor-cell related changes, as well as changes in 
tumor surrounding microenvironment contribute to the inefficacy of standard 
radiotherapy.  
In the current study, we evaluated the role of tumor infiltrating CD63+ in-
flammatory and immune cells, representing one constituent of tumor micro-
milieu, on radiotherapy treatment response and survival of GBM patients. The 
presence of CD63+ cells was detected by immunohistochemical staining proce-
dure, which revealed wide variability in these cell numbers: evaluated tumor 
samples contained from 10.3 CD63+ cells to as much as 134.5 CD63 cells per 
microscopic field. In previous studies, CD63 expression has been evaluated in a 
different manner. For example, CD63 expression has been reported in GBM 
tissue microarray cores as labeling indexes, representing the percentage of 
positively immunostained tissue area [156]. Also, gene expression analyses in 
GBM tumor tissue that always contain also some proportions of non-tumor 
components have revealed higher levels of CD63 [157,158]. However, in these 
previously described studies, it is not exactly clear, whether CD63 expression 
relates more to tumor cells and/or normal tissue compartments, including 
inflammatory and immune cells, which makes the comparison of the studies 
difficult. Our study additionally revealed the association between the numbers 
of CD63+ tumor infiltrating inflammatory and immune cells and the percentage 
of necrosis in GBM tissue. This shows that next to cancer cells, inflammatory 
and immune response might be mediated through other components of the 
tumor microenvironment.  
Median survival time of the entire study group was 10.0 months. Present 
study revealed, however, that the survival time clearly depended on the number 
of tumor infiltrating CD63+ inflammatory and immune cells. Median survival 
times for patients with low (<median) and high (≥median) numbers of CD63+ 
inflammatory and immune cells were 9.0 months and 12.0 months respectively. 
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Therefore, patients whose tumors were infiltrated with higher number of inflam-
matory and immune cells, had better treatment response and lived significantly 
longer compared to those whose tumors had fewer tumor infiltrating CD63+ 
cells. Given the dismal prognosis of GBM, the gain in overall survival of 3 
months is remarkable. To the knowledge of authors, there are no other clinical 
studies that would have evaluated the prognostic signifycance of the amount of 
tumor infiltrating CD63+ inflammatory and immune cells after GBM radio-
therapy. However, it has been shown earlier that co-expression of tissue 
inhibitor of metalloproteinase-4 (TIMP-4) and CD63 is associated with reduced 
survival of GBM patients [156]. In the latter study, however, CD63 expression 
was evaluated in only 3 small GBM tissue microarray cores and reported as 
labeling indexes, representing the percentage of positively immunostained 
tissue area comprising both tumor and inevitably also non-tumor tissue. 
Moreover, in univariate analysis, TIMP-4 and CD63 labeling indexes alone did 
not reach statistical significance in relation to median cancer specific survival.  
Our study raises the possibility that both inflammation and immune reaction 
might influence radiation sensitivity of GBM cells and thereby treatment out-
come. According to a dominating belief, targeting the inflammatory signaling 
pathways might offer a good opportunity to improve clinical cancer outcome, 
since irradiation itself leads to additional synthesis of several pro-inflammatory 
factors and inflammatory response is one of the hallmark of radiation-induced 
normal tissue side effects [159,160]. However, there are several clinical studies, 
although in other types of cancer, showing that blocking of inflammatory 
pathways does not enhance treatment response of radiotherapy and concomitant 
chemotherapy. For example, blocking of inflammatory enzyme cyclo-
oxygenase-2 (COX-2), which is also expressed in GBM tissues, with a selective 
inhibitor of COX-2 celexocib does not improve treatment efficacy and survival 
in patients with stage IIIA/B non-small cell lung cancer [111,161]. Similar 
disappointing results with COX-2 inhibitor celexocib have been reported in 
pancreatic cancer, as well as in rectal cancer [162,163].  In contrast to latter 
studies but in line with our data, a higher grade of inflammatory infiltration in 
tumor tissue that was defined by 2 pathologists in a blinded fashion in 10–20 
microscopic fields in hematoxylin stained sections, related to favorable survival 
of rectal cancer patients receiving preoperative radiotherapy [164].   
In the tumor microenvironment, an intensive interaction between tumor cells 
and infiltrating immune cells, most frequently macrophages and T-cells occur 
[165, 160]. The presence of tumor infiltrating T-cells has also been reported in 
GBM tissues [110]. Similarly to our study, increased immune cell infiltration is 
a significant independent variable contributing to longer survival in high grade 
astrocytomas and glioblastoma [166,167]. Additionally, the expression of 
immune genes in GBM has been associated with prolonged progression-free 
survival and immunohistochemically detected expression of CD3 and CD68 
cells (markers of T-cells and macrophages) is significantly more frequent in 
responders to radiotherapy than in non-responders, confirming the role of tumor 
infiltrating immune cells in modulating radiation effects in GBM [168]. It is 
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believed that tumor infiltrating resident leukocytes detect danger signals form 
cytotoxic therapy that results in subsequent activation of both innate and 
adaptive immune cells [169,170]. Indeed, it has been previously reported that 
irradiation influences tumor immune response through release of proinflam-
matory molecules and cytokines, antigen presentation, increased homing of 
inflammatory cells, enhanced T-cell activation and cytotoxic immune response, 
as well as through inhibition of immunosuppressive cells [170].     
Previous studies have shown that pro-inflammatory and immune-based 
mechanisms might have a potential to influence the response to conventional 
cytotoxic therapy and thereby diminish tumor progression and prolong patients 
survival. In fact, signs from early clinical trials confirm that the combination of 
immune-based therapies and chemotherapy, which is one form of cytotoxic 
treatment, result indeed in synergistic effects. In GBM patients (mostly with 
recurrent tumors), autologous dentritic cell vaccination prior chemotherapy 
significantly prolonged time to tumor recurrence and survival [171]. Moreover, 
vaccine responders have been shown to exhibit significantly longer times to 
post chemotherapy tumor progression and survival than nonresponders [172]. 
Therefore, concomitant immune-therapy with cytotoxic anti-cancer treatment 
holds great promise and the exact sequencing and combination of different 
treatment modalities (including radiotherapy) should be defined in the near 
future. 
In conclusion, enhanced inflammatory and immune response in GBM tissue 
corresponds to better survival after postoperative radiotherapy. Although CD63 
immunohistochemical expression does not distinguish exact cell types that have 
the greatest impact on GBM treatment response, our study created a good 
platform for further clarifying studies. 
 
 
6.4. Inflammation, ICAM-1 and VEGFR-2 
In the present study, we evaluated the impact of tumor microenvironment on the 
expression level of VEGFR-2 – one of the main targets of antiangiogenic drugs. 
Foremost, the possible role of inflammatory reaction was assessed. Inflamma-
tory reaction was evaluated by two means. First, visual inflammation (based on 
the presence of tissue edema and inflammatory cell infiltration) was estimated 
in hematoxylin-eosin stained sections by experienced pathologist. Afterwards, 
to reduce subjectivity, a digital IHC image analysis was performed in ICAM-1 
stained sections. ICAM-1 was chosen as a marker of inflammation since this 
transmembrane glycoprotein can be induced in response to a number of stimuli, 
including inflammatory mediators, hormones and cellular stresses [173,174]. 
Moreover, endothelial ICAM-1 is considered to represent the most important 
adhesion molecule for leukocyte recruitment to inflamed sites [175–177].  
All glioblastoma samples showed various levels of visually confirmed 
inflammatory reaction. This is not surprising since inflammation is considered 
one of the characteristic histopathological features of glioblastoma [178]. Also, 
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the expression of ICAM-1 was present in all digitally analyzed individual tumor 
samples, which is in good accordance with previous studies, where compared to 
peritumoral ICAM-1 expression significantly higher expression of ICAM-1 has 
been detected in GBM tumor areas both in gene and protein levels [179–181]. 
In GBM cells, ICAM-1 expression has been shown to increase following 
stimulation with pro-inflammatory cytokines, such as interleukin-1β (IL-1β), 
tumor necrosis factor-alpha (TNFα) and interferon-gamma (IFN-γ) [179,182], 
indicating that ICAM-1 is one of the inflammatory mediators also in this type of 
cancer. 
In GBM tissues, different numbers of VEGFR-2+ blood vessels and endo-
thelial levels of VEGFR-2 were detected. Previous studies have shown that in 
normal brain, low or undetectable endothelial expression of VEGFR-2 can be 
found, however, in gliomas, the proportion of VEGFR-2+ vessels and 
endothelial VEGFR-2 expression increases with tumor grade, being the highest 
in GBM [183,184]. Our study revealed that also in most aggressive glioma – 
GBM – the extent of VEGFR-2 expression may vary. Additionally, present 
study showed that the expression of VEGFR-2 depends on inflammatory 
reaction in tumor tissue: the higher endothelial VEGFR-2 expression the higher 
extent of inflammation. Moreover, this association was seen for both assess-
ments of inflammatory reaction (visual and computer software based).  
Angiogenesis is a tightly controlled process that in a number of pathological 
conditions, including cancer and inflammation, may become aberrant [185]. 
Different factors produced by tissues are capable of promoting or inhibiting 
blood vessel proliferation, whereas in normal status, the balance between angio-
genic and angiostatic factors exists. In inflammation, this balance is clearly 
inclined toward angiogenic factors and angiogenesis [186].  
Although the link between inflammation and angiogenesis has received 
much attention only recently, there is a substantial body of evidence showing 
close association between these two processes. Previous studies have described 
that angiogenic factors exhibit both pro-angiogenic and pro-inflammatory 
effects, inflammatory cells are able to produce large quantities of pro-angio-
genic factors and both processes (inflammation and angiogenesis) are capable of 
potentiating each other [186]. For example, VEGF that exerts majority of its 
angiogenic effects by binding to VEGFR-2, has also been shown to induce 
adhesion molecules on endothelial cells during inflammation [187]. In endo-
thelial cells, treatment with VEGF results in an increase of both ICAM-1 
mRNA, as well as protein expression [188]. Moreover, VEGF increases leuko-
cyte adhesiveness to endothelial cells, which is the first step of leukocyte 
trafficking into inflamed tissue [188]. Next to these effects, VEGF enhances 
vascular permeability and causes vasodilatation, potentiating thereby inflam-
mation through formation of tissue edema [116,189]. At the same time, hyper-
permeability is also involved in pathological angiogenesis [189]. Additionally, 
inflammatory and angiogenic processes involve similar cell types. Inflammatory 
cells, namely monocytes, macrophages, T lymphocytes and neutrophils, partici-
pate in the angiogenesis by secreting cytokines that affect endothelial cell 
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functions, proliferation, migration and activation [190]. Macrophages, present in 
the inflammatory infiltrate, produce a broad array of angiogenic growth factors 
and cytokines, generate channels for blood flow through proteolytic mecha-
nisms, and promote the remodeling of arterioles into arteries [185]. Inflam-
matory dendritic cells stimulate similarly angiogenesis by secreting angiogenic 
factors and cytokines, as well as by promoting pro-angiogenic activity of T 
lymphocytes [185]. Previous studies have also shown that pro-inflammatory 
cytokines, which are always present in inflamed tissue, mediate also endothelial 
expression of VEGFR-2 [191,192]. Latter is in line with our findings since 
positive correlation was found between the extent of VEGFR-2 expression and 
inflammatory response in GBM tissue.     
There are several clinical situations, where inflammatory reaction in GBM 
may be suppressed. These particularly include the use of anti-inflammatory 
drugs, such as steroids and nonsteroidal anti-inflammatory drugs (NSAIDs) to 
manage tumor surrounding inflammation and edema [193]. Whether these very 
commonly used medicines influence also treatment efficacy of antiangiogenic 
drugs through diminishing inflammatory response and thereby the expression of 
VEGFR-2, remains unclear. Nevertheless, our data point toward the possibility 
that this association might exist. This is also supported by studies where 
dexamethasone, most frequently used steroid in GBM patients, has been shown 
to inhibit the effects of pro-inflammatory cytokines, VEGF mRNA expression, 
VEGFR-2 expression, as well as macrophage infiltration [192,194,195]. 
In conclusion, our study showed that the expression of VEGFR-2 – one of 
the main targets of antiangiogenic drugs - depends on GBM microenvironment. 
Importantly, higher endothelial VEGFR-2 levels were seen in the presence of 
more pronounced inflammation, whereas in less inflamed tissues only weak 
expression of VEGFR-2 was found. Latter has to be taken into consideration 
when treatment approaches that block VEGFR-2 signaling are designed. 
 
The present PhD study has several limitations. These include retrospective data 
collection and small number of patients, which considered small Estonian popu-
lation and rare tumor type is inevitable. Also, some important variables, such as 
tumor O6-methylguanine-DNA methyltransferase (MGMT) methylation status, 
isocitrate dehydrogenase 1 (IDH1) gene mutation status, recursive partitioning 
analysis (RPA) and patient’s quality of life scores were not recorded. 
Nevertheless, this study showed that several aspects in GBM therapy might be 
improved and modification of not only GBM cells but also stem cells and tumor 
microenvironment might be necessary to find more efficacious treatment 
strategies to fight this devastating disease. Latter, however, has to be clarified in 
further preclinical and clinical studies that may be based on ideas that rose in 
the present study.  
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7. CONCLUSIONS 
 
1. The survival of GBM patients receiving postoperative radiotherapy depends 
on tumor expression of DNA-PK. GBM patients with high tumor levels of 
DNA-PK are more resistant and respond less to standard radiotherapy that 
consequently result in significantly shorter survival times. Further studies are 
needed to clarify whether DNA-PK inhibitors might have a potential to 
radiosensitize GBM and improve the treatment outcome of this disease. 
2. In patients with GBM, there is no association between higher proportion of 
tumor stem cells and the aggressiveness of disease. In contrast, in patients 
with higher stem cell proportion, significantly longer survival times after 
postoperative radiotherapy were achieved. Underlying reasons and possible 
higher sensitivity of GBM stem cells to fractionated radiotherapy should be 
clarified in further studies.    
3. Enhanced inflammatory and immune response in GBM tissue corresponds to 
better survival after postoperative radiotherapy. Therefore, pro-inflammatory 
and immune-based therapies might have a potential to influence the response 
to conventional cytotoxic therapy and thereby diminish tumor progression 
and prolong patients survival.  
4. The expression of VEGFR-2 – one of the main targets of antiangiogenic 
drugs – depends on GBM microenvironment. Higher endothelial VEGFR-2 
levels were seen in the presence of more pronounced inflammation, whereas 
in less inflamed tissues only weak expression of VEGFR-2 was found. Latter 
may be one of the reasons of inefficacy of antiangiogenic drugs and should 
be taken into consideration when GBM treatment approaches that block 
VEGFR-2 signaling are designed. 
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9. SUMMARY IN ESTONIAN 
 
Multiformne glioblastoom: võimalused parandamaks  
kasvajavastase ravi efektiivsust 
Multiformne glioblastoom (MGB) on kõige agressiivsem aju primaarne paha-
loomuline kasvaja täiskasvanutel, mille ravitulemused on siiani ebarahuldavad 
(keskmine elulemus ca 1 aasta). MGB diagnoosiga haigete elulemust ei ole 
siiani suudetud märkimisväärselt pikendada vaatamata aastakümneid kestnud 
uurimustöödele. Alates 1978. aastast on MGB standardraviks olnud kasvaja 
kirurgiline eemaldamine koos sellele järgneva postoperatiivse kiiritusraviga 
ning medikamentoosse raviga (keemiaravi, sihtmärkravi). MGB on oma iseloo-
mult resistentne haigus, sest nii postoperatiivse kiiritusravi kui ka medika-
mentoosse raviga on võimalik saavutada ainult haiguse lühiajalist stabilisat-
siooni. Paraku surevad ravi järgselt enamus haigetest (99%) lokaalse retsidiivi 
tõttu ajukoes, mistõttu peetakse MGB üheks kõige raskemini ravitavaks paha-
loomuliseks kasvajaks. Ravitulemuste parandamise üheks alustalaks on ravi-
resistentsust põhjustavate mehhanismide väljaselgitamine.  
Käesoleva töö põhieesmärgiks oli leida võimalusi MGB-vastase ravi 
efektiivsuse tõstmiseks ning selleks: 
1. hinnati, kas MGB kõrge reparatsiooniensüümide (PARP-1 ja DNA-PK) tase 
on seotud halvema ravivastusega ning seeläbi haigete lühema elulemusega, 
2. hinnati, kas CD133+ kasvaja tüvirakud, mida eelnevate eelkliiniliste uurin-
gute põhjal on peetud kõige radioresistentsemateks kasvajarakkudeks, 
mõjutavad MGB diagnoosiga haigete ravitulemusi ja elulemust, 
3. hinnati, kas CD63+ kasvajat infiltreerivad põletiku- ja immuunrakud mõju-
tavad MGB diagnoosiga haigete ravitulemusi ja elulemust, 
4. hinnati kasvaja mikrokeskkonna, eelkõige põletiku mõju ühe kõige olu-
lisema angiogeneesi inhibiitorite sihtmärgi, VEGFR-2 ekspressioonile. 
Uuringusse kaasati MGB diagnoosiga haiged (max n=42), kes said postope-
ratiivset kiiritusravi Tartu Ülikooli Kliinikumis või Põhja-Eesti Regionaal-
haiglas aastatel 2006–2008. Operatsiooni käigus eemaldatud kasvajakoes hin-
nati hematoksüliin-eosiin värvingu järgselt nekroosi ulatust (%) ning põleti-
kulist reaktsiooni (1=nõrk, 2=mõõdukas, 3=raske põletikuline reaktsioon). 
Immuunhistokeemilise värvingu järgselt hinnati kasvajarakkudes DNA reparat-
siooniensüümide (PARP-1, DNA-PK) värvumise taset (skoor 0–3), CD133+ 
MGB tüvirakkude osakaalu mikroskoobi vaatevälja kohta (%), CD63+ põletiku- 
ja immuunrakkude arvu mikroskoobi vaatevälja kohta, ICAM-1 ekspressiooni 
optilist tihedust (kvantitatiivse pikseli analüüsi tarkvara abil) ning VEGFR-2 
endoteliaalse värvumise intensiivsust (skoor 0–3). Lisaks eelnevatele hinnati 
DNA reparatsiooniensüümide taseme, CD133+ tüvirakkude proportsiooni ning 
kasvajat infiltreerivate CD63+ põletiku- ja immuunrakkude seost patsientide 
üldise elulemusega (Kaplan-Meieri elulemuse analüüs, mitmemõõtmeline ana-
lüüs). Korrelatsioonide analüüsimisel kasutati Pearsoni korrelatsiooni testi. 
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Kasvajarakkude PARP-1 ja DNA-PK värvumise tasemed varieerusid 
vastavalt vahemikus 1,2–2,8 ja 0,8–2,8. PARP-1 keskmine ja mediaanväärtus 
olid vastavalt 1,96±0,50 (keskmine±standardhälve) ning 2,0. DNA-PK kesk-
mine ja mediaanväärtus olid vastavalt 2,02±0,49 (keskmine±standardhälve) ja 
2,0. Kogu MGB diagnoosiga haigete grupi üldise elulemuse mediaan oli 10,0 
kuud (95% UV 8,1–11,9). Elulemus ei sõltunud PARP-1 tasemest (p=0,93), 
kuid sõltus oluliselt kasvajarakkude DNA-PK tasemest (p=0,02). Patsientide 
elulemus madala (<mediaan) ja kõrge (≥mediaan) DNA-PK tasemega oli 
vastavalt 13,0 kuud (95% UV 10,7–15,3) ja 9,0 kuud (95% UV 7,2–10,8). 
Mitmemõõtmeline analüüs kinnitas, et DNA-PK tase on üldise elulemuse 
oluline prognostiline tegur (riskisuhe 3,9, 95% UV 1,5–10,7, p=0,01). 
CD133+ tüvirakkude osakaal oli MGB koes väga varieeruv, jäädes erine-
vatel patsientidel vahemikku 0,5–82%. Tüvirakkude osakaalu keskmine ja 
mediaanväärtus olid vastavalt 33%±24%  (keskmine±standardhälve) ning 28%. 
Kogu grupi üldise elulemuse mediaan oli 10,0 kuud (95% UV 9,0–11,0). 
Elulemus sõltus märkimisväärselt CD133+ rakkude osakaalust (p=0,02). 
Patsientide elulemus madala (<mediaan) ja kõrge (≥mediaan) CD133+ tüvi-
rakkude osakaaluga oli vastavalt 9,0 kuud (95% UV 7,6–10,5) ja 12,0 kuud 
(95% UV 9,3–14,7). Mitmemõõtmeline analüüs kinnitas, et CD133+ tüvirakku-
de osakaal on oluline prognostiline tegur (riskisuhe 2,0 95% UV 1,0–3,8, 
p=0,04). 
Kasvajat infiltreerivate CD63+ põletiku- ja immuunrakkude arv mikroskoobi 
vaatevälja kohta varieerus MGB diagnoosiga haigetel vahemikus 10,3–134,5. 
CD63+ rakkude keskmine arv ja mediaanväärtus olid vastavalt 45,3±27,2 
(keskmine±standardhälve) ning 39,6. Kogu grupi üldise elulemuse mediaan oli 
10,0 kuud (95% UV 9,0–11,0). Elulemus sõltus märkimisväärselt kasvajat 
infiltreerivate CD63+ põletiku- ja immuunrakkude arvust (p=0,003). Patsientide 
elulemus madala (<mediaan) ja kõrge (≥mediaan) CD63+ põletikuliste rakkude 
arvuga olid vastavalt 9,0 kuud (95% UV 8,1–9,9) ja 12,0 kuud (95% UV 8,5–
15,5). Mitmemõõtmeline analüüs kinnitas, et CD63+ põletikurakkude arv on 
oluline prognostiline tegur (riskisuhe 2,4 95% UV 1,2–5,1, p=0,02). 
MGB koes visuaalselt hinnatud põletikulise reaktsiooni keskmine skoor oli 
uuringugrupis 1,9±0,7 (keskmine±standardhälve). Digitaalse pikseli analüüsiga 
hinnatud ICAM-1 ekspressiooni optiline tihedus varieerus vahemikus 17,6–
154,9 ühikut. Grupi keskmine ICAM-1 optiline tihedus oli 57,0±27,1 (kesk-
mine± standardhälve). Grupi keskmine endoteliaalse VEGFR-2 värvumise 
intensiivsus oli 1,2±0,8 (keskmine±standardhälve). Märkimisväärne korrelat-
sioon leiti endoteliaalse VEGFR-2 ekspressiooni ja põletiku ulatuse vahel 
(p<0,01). Samuti esines märkimisväärne seos endoteliaalse VEGFR-2 ekspres-
siooni ja kasvajakoe ICAM-1 optilise tiheduse vahel (p=0.03). 
Käesolev doktoritöö näitas, et postoperatiivset kiiritusravi saavate MGB 
diagnoosiga haigete elulemus sõltub kasvaja DNA-PK tasemest. Patsiendid, 
kelle kasvajakoes oli kõrge DNA-PK tase, allusid ravile halvemini ning elasid 
lühemalt. Seetõttu tuleks edasistes uuringutes hinnata, kas DNA-PK inhibiitorid 
võiksid tõsta kasvajarakkude tundlikkust kiiritusravile ning parandada seeläbi 
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ravitulemust. Käesoleva töö raames täheldati, et kliinilised andmed ei kinnita 
seost MGB CD133+ tüvirakkude suurema osakaalu ning kasvaja agressiivsema 
kulu vahel. Suurema CD133+ tüvirakkude osakaaluga patsiendid saavutasid 
postoperatiivse kiiritusravi järgselt pikemalt kestva haiguse remissiooni ja 
pikema elulemuse. Selle põhjused vajavad selgitamist edasistes uuringutes. 
Lisaks eelnevale leiti, et  kasvajat infiltreerivad CD63+ põletiku- ja immuun-
rakud omavad soodsat toimet MGB haigete elulemusele. Haigetel, kellel 
kasvajakude sisaldas postoperatiivse kiiritusravi eelselt rohkem põletiku- ja 
immuunrakke, oli oluliselt pikem elulemus. Eelnevast tulenevalt võiks seega 
edasistes uuringutes vaadelda, kas põletikku- ja immuunreaktsiooni võimen-
davad ravimeetodid koos standardse tsütotoksilise kasvajavastase raviga paran-
daksid MGB ravitulemust. Samuti selgus käesolevast tööst, et MGB ravis 
laialdaselt testitud angiogeneesi inhibiitorite ühe olulise sihtmärgi – VEGFR-2 – 
ekspressioon sõltub kasvajakoe põletiku ulatusest. VEGFR-2 ekspressiooni 
sõltuvus tuumori põletikulisest mikrokeskkonnast võib olla üheks angiogeneesi 
inhibiitorite ebaefektiivsuse põhjuseks. 
Kokkuvõtvalt võib öelda, et MGB ravitulemuste parandamiseks on mitmeid 
võimalusi ning efektiivsema kasvajavastase ravi läbiviimiseks ei tuleks mõju-
tada ainult kasvajarakke, vaid ka kasvaja tüvirakke ning kasvaja mikrokesk-
konda. Doktoritöö raames tekkinud ideid on kavas testida edasistes eelkliini-
listes ning kliinilistes uuringutes. 
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